国睿科技股份有限公司内部审计制度 （2025 年 12 月修订） 第一章 总则 第一条 为了加强内部审计工作，建立健全内部审计制度，提升内部审计工 作质量，充分发挥内部审计作用，促进公司内部各管理层行为的合法性、合规 性，为管理层正确决策提供可靠的信息和依据，保护投资者合法权益，不断提 高企业运营的效率及效果，依据《审计署关于内部审计工作的规定》、《中国 内部审计准则》、《上海证券交易所上市公司自律监管指引第1号——规范运 作》等法律法规及《公司章程》的规定，制定本制度。 第二条 本制度所称内部审计，是指公司内部纪检监察审计部门依据国家有 关法律法规、财务会计制度和公司内部管理规定，对公司及所属控股子公司财 务收支、经济活动、内部控制、风险管理实施独立、客观的监督、评价和建 议，以促进公司完善治理、实现目标的活动。 第三条 本制度所称内部控制，是指为了保证公司战略目标的实现，而对公 司战略制定和经营活动中存在的风险予以管理的相关制度安排，是公司董事 会、高级管理人员及其他有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （四）确保公司信息披露的真实、准确、完整和公平 ...

国睿科技股份有限公司 董事和高级管理人员离职管理制度 第一章 总则 第一条 为了加强对国睿科技股份有限公司（以下简称公司）董事、高级管 理人员离职事项的管理，保障公司治理稳定性及维护股东合法权益，根据《中华 人民共和国公司法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》《上海证券交易所股票上市规则》等法律、法规和规范性文件以及《国睿科 技股份有限公司章程》相关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事（含独立董事）及高级管理人员。 第三条 公司董事、高级管理人员离职管理应遵循以下原则： （一） 合法合规原则。严格遵守国家法律法规、监管规定及《公司章程》 的要求。 （二） 公开透明原则。公司应及时、准确、完整地披露董事、高级管理人 员离职相关信息。 （三） 平稳过渡原则。确保董事、高级管理人员离职不影响公司正常经营 和治理结构的稳定性。 （四） 保护股东权益原则。保护公司及全体股东的合法权益。 第二章 离职情形与生效条件 第四条 公司董事、高级管理人员离职包含任期届满未获连任、主动辞任、 被解除职务以及其他导致董事、高级管理人员实际离职等情形。 （一）董事任期届满未及时 ...

国睿科技股份有限公司内部审计制度 （2025 年 12 月修订） 第一章 总则 第一条 为了加强内部审计工作，建立健全内部审计制度，提升内部审计工 作质量，充分发挥内部审计作用，促进公司内部各管理层行为的合法性、合规性， 为管理层正确决策提供可靠的信息和依据，保护投资者合法权益，不断提高企业 运营的效率及效果，依据《审计署关于内部审计工作的规定》、《中国内部审计 准则》、《上海证券交易所上市公司自律监管指引第1号——规范运作》等法律法 规及《公司章程》的规定，制定本制度。 第二条 本制度所称内部审计，是指公司内部纪检监察审计部门依据国家有 关法律法规、财务会计制度和公司内部管理规定，对公司及所属控股子公司财务 收支、经济活动、内部控制、风险管理实施独立、客观的监督、评价和建议，以 促进公司完善治理、实现目标的活动。 第三条 本制度所称内部控制，是指为了保证公司战略目标的实现，而对公 司战略制定和经营活动中存在的风险予以管理的相关制度安排，是公司董事会、 高级管理人员及其他有关人员为实现下列目标而提供合理保证的过程： （一）遵守国家法律、法规、规章及其他相关规定； （二）提高公司经营的效率和效果； 第四条 公司 ...

证券代码：600562 证券简称：国睿科技 公告编号：2025-035 国睿科技股份有限公司 第十届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2.本次会议的通知及会议资料在会议召开前送达全体董事。 3.本次会议由董事长郭际航女士召集，于 2025 年 12 月 19 日在南京市建邺 区江东中路 359 号公司会议室以现场结合通讯方式召开。 4.本次会议应出席董事 9 人，实际出席董事 9 人。 二、会议审议情况 1.审议通过了《关于对全资子公司南京国睿微波器件有限公司增资的议案》。 同意子公司南京国睿微波器件有限公司采用资本公积转增实收资本方式增 加注册资本 3,200 万元，增资完成后注册资本由 1,800 万元变更为 5,000 万元， 国睿科技持股仍为 100%。 议案表决结果为：同意 9 票，反对 0 票，弃权 0 票。 2.审议通过了《关于大额资金支付的议案》。 一、会议召开情况 根据《公司"三重一大"决策管理办法》及董事会授权文件，同意公司向子 公司南京国睿防务系统有限公司支付 20 ...

Core Insights - The report emphasizes the importance of "globalization and AI+" in advancing high-quality development in the defense and military industry, highlighting the need for modernization and efficiency improvements in military systems [5][30][34] - The investment strategy focuses on balancing value and growth, with traditional sectors entering an S-curve evolution phase while new demands and replacements coexist [5][30] Section Summaries 1. Current Development Stage from the S-Curve Perspective - The defense and military industry is in a growth phase, with traditional sectors experiencing rapid development during the previous five-year plan, but not yet entering a slowdown [16][26] - The S-curve model indicates that the industry lifecycle includes multiple product lifecycles, with the current focus on extending product lifespans through innovation [23][24] 2. S-Curve Cycle Expansion - Global military trade remains robust, emphasizing the importance of lifecycle management from equipment to services [9][18] - The report anticipates that the demand for large aircraft and low-altitude economic activities will accelerate due to supportive policies [9][28] 3. S-Curve Cycle Evolution - Supply chain reforms are crucial for reducing costs and complexity, enhancing the focus on maintenance and repair services [9][33] - The integration of unmanned systems and intelligent technologies is expected to drive significant advancements in military capabilities [9][51] 4. New Cycle of the S-Curve: Emerging Industries - The report identifies commercial aerospace, AI, controllable nuclear fusion, quantum information, and deep-sea technology as key areas for future growth [9][57][65] - The acceleration of technological advancements and policy support is expected to unlock new market opportunities in these sectors [9][58] 5. Investment Recommendations - The report recommends focusing on companies that align with the evolving S-curve, particularly those involved in supply chain reform, maintenance, and unmanned systems [5][30] - Specific companies highlighted for investment include 航发动力, 中航高科, and 国睿科技, among others, which are positioned to benefit from these trends [6][9]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301306 | 西测测试 | 90.40 | 14.94% | 17.30万 | 15.27 乙 | | 002413 | 雷科防务 | 9.98 | 10.03% | 576.07万 | 54.75 Z | | 301517 | 陕西华达 | 67.85 | 6.88% | 23.28万 | 15.64亿 | | 600562 | 国睿科技 | 28.30 | 5.05% | 33.27万 | 9.32 G | | 001270 | *ST锭昌 | 64.28 | 5.00% | 1530.0 | 983.48万 | | 688011 | 新光光电 | 48.75 | 4.59% | 4.96万 | 2.42亿 | | 300762 | 上海剪讯 | 35.71 | 4.20% | 137.99万 | 48.75 Z | | 002179 | 中航光电 | 33.59 | 4.09% | 47.93万 | 16.00亿 | | 688081 | ...

Core Insights - The defense and aerospace industry is experiencing sustained high demand, particularly in the two aircraft sectors and commercial aerospace, which are seen as new growth drivers [2][5][13] - The report highlights the increasing frequency of commercial space launches, with companies like SpaceX targeting a valuation of $1.5 trillion as they prepare for an IPO [5][14] - Investment opportunities are identified in various sectors, including domestic demand and overseas expansion, AI-driven upgrades in military technology, and the potential for new materials and technologies in aviation and space [5][15] Industry Overview - The report notes that the demand for high-end aviation equipment is expected to continue, with significant opportunities for domestic engine replacements in the civil aviation market [23] - The commercial aerospace sector is seeing a notable increase in aircraft deliveries, with a reported 44% year-on-year growth in the delivery of wide-body aircraft as of October 2025 [5][13] - The report emphasizes the importance of strategic partnerships, such as the long-term supply agreement between Yingliu Aviation and Ansaldo Energia, which marks a shift towards large-scale collaboration [5][13] Company Analysis - Companies like AVIC Shenyang Aircraft Corporation and AVIC Xi'an Aircraft Industry Group are highlighted for their potential to benefit from increased domestic and international demand [15][29] - The report discusses the strong growth prospects for companies involved in AI-driven military upgrades, recommending a focus on firms like Ruichuang Micro-Nano and AVIC Optoelectronics [15][18] - The financial outlook for key companies is optimistic, with projected earnings growth and favorable valuation metrics, such as a dynamic PE ratio of approximately 40X for Ruichuang Micro-Nano [18][19] Market Performance - The report indicates that the China Securities Military Industry Index has shown a weekly increase of 2.53%, with a year-to-date increase of 27.99% as of the report date [36] - The military sector has outperformed major indices, indicating strong investor interest and confidence in the defense and aerospace markets [36] Investment Recommendations - The report suggests focusing on companies that are well-positioned to capitalize on the expanding domestic and international markets, particularly those involved in military and aerospace technology [15][23] - Specific companies recommended for investment include AVIC Shenyang, AVIC Xi'an, and Ruichuang Micro-Nano, among others, due to their strategic positioning and growth potential [15][18][29]

关于子公司项目预中标的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近期，国睿科技股份有限公司接到子公司芜湖国睿兆伏电子有限公司（简称国睿兆伏）通知，国睿兆伏 投标的"GXLF项目片放泵浦源"项目发布了评标结果，国睿兆伏为该项目的中标候选人，该结果在中国 工程物理研究院招投标信息网（ztbxx.caep.ac.cn）上进行了公示，公示期为2025年12月8日至2025年12 月12日。 本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据片放泵浦源功能及技术指标 要求完成相应的工程设计、加工制造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报 价为人民币76,000,000.00元（柒仟陆佰万元整）。 证券代码：600562 证券简称：国睿科技 公告编号：2025-034 国睿科技股份有限公司 国睿兆伏后续将在收到中标通知书后，履行合同签订等程序，敬请投资者注意投资风险。 特此公告。 国睿科技股份有限公司董事会 2025年12月13日 ...

Group 1 - Moer Thread plans to use up to 7.5 billion yuan of idle raised funds for cash management, with a usage period of 12 months [1] - O-film plans to purchase 8.46% equity of its subsidiary Anhui Che Lian for a total of 3.64 billion yuan, increasing its ownership from 78.54% to 87% [2] - ST Lian Shi applies to revoke the delisting risk warning as its restructuring plan has been completed [3] Group 2 - Weirli signs a strategic cooperation framework agreement with Primech Holdings to build an industrial robot cooperation platform [4] - Race Intelligent plans to raise no more than 1.144 billion yuan through a private placement for core components of intelligent equipment [5] - Renfu Pharmaceutical's stock will be subject to other risk warnings and will be suspended for one day starting December 15 [6] Group 3 - Yongding Co. clarifies that its subsidiary Dongbu Superconductor does not directly manufacture controllable nuclear fusion devices [7] - Rongbai Technology plans to acquire part of Guizhou Xinren's equity and increase its capital to achieve control [9] - ST Hu Ke is under investigation by the Securities Regulatory Commission for suspected information disclosure violations [10] Group 4 - Yunnan Ge Industry plans to establish a subsidiary focused on organic germanium-related products [11] - Greenme intends to acquire 16.38% equity of Henan Recycling Group for 400 million yuan [12] - Jiangzhong Pharmaceutical plans to change its name to China Resources Jiangzhong Pharmaceutical [13] Group 5 - Jiangsu Guoxin's subsidiary Ma Zhou Power has completed the trial operation of a 1,000 MW coal-fired power generation unit [16] - Longsheng Technology plans to invest in a center for embodied intelligent robots [18] - Guangzhou Development has received approval for the registration of 8 billion yuan medium-term notes and 6 billion yuan short-term financing notes [19] Group 6 - China Merchants Port reported a container throughput of 17.248 million TEUs in November, a year-on-year increase of 6.4% [20] - Tianma Technology reported a total eel output of approximately 11,415.87 tons from January to November [21] Group 7 - Xilong Science plans to reduce its stake by up to 1% [22] - Xicet Testing's actual controller plans to transfer 5% of the company's shares [23] - Oppein Home's actual controller plans to increase its stake by 50 million to 100 million yuan [24] Group 8 - Maide Medical plans to repurchase shares worth 20 million to 40 million yuan [25] - Baicheng Pharmaceutical's major shareholder increased its stake by 0.85% [26] - Mengbaihe's major shareholder plans to reduce its stake by up to 1% [27] Group 9 - Xian Dao Ji Dian's shareholder has reduced its stake by 1.70% [28] - Yaxiang Integration's shareholder reduced its stake by 41,400 shares [29] - Zhiwei Intelligent's actual controller has reduced its stake, bringing the total holding to 69% [30] Group 10 - Jincheng Co.'s actual controller plans to reduce its stake by up to 0.97% [31] - Jianghua Micro's chairman has reduced his stake by 1.09% [32] - COSCO Shipping Energy signed a shipbuilding contract worth 7.882 billion yuan [33] Group 11 - Dayu Water Saving's subsidiary is expected to win two high-standard farmland construction projects [34] - Guorui Technology's subsidiary is a candidate for the GXLF project [36] - ST Zhisheng has won a smart city governance project worth 104 million yuan [37]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]